Amgen examines barriers to PCSK9 inhibitor access

Amgen Inc. (NASDAQ:AMGN) reported data from two retrospective studies suggesting that payer utilization management criteria does not accurately identify high-risk patients who should have access to PCSK9 inhibitors.

The first study found that 65% of 3,472 commercially insured

Read the full 372 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE